Introduction/Background Patients with intermediate-risk factors after radical hysterectomy (RH) are known to have a greater recurrence risk, suggesting most worldwide guidelines the use radiotherapy (RT) as adjuvant treatment. However, its benefit is a controversial issue nowadays, since several recent studies do not find differences in survival between those patients who receive adjuvant RT and those who do not.

Methodology We conducted a retrospective study including consecutive patients diagnosed with early-stage cervical cancer (IA1 with LVSI, IA2, IB1, IB2 and IIA1 of FIGO 2018 classification) in La Paz University Hospital between January 2005 and December 2022. All patients underwent primary surgical treatment by RH with pelvic lymphadenectomy (PL) or pelvic sentinel lymph node biopsy (SLNB). Cox regression model was used to perform univariate and multivariate analyses of prognostic factors to predict survival outcomes. Kaplan-Meier survival analysis was used for the calculation of overall survival (OS) and disease-free survival (DFS).

Results From the initial cohort of 135 patients, 121 were included in this retrospective study. The median age was 48.4 years (SD 11.5) and the most frequent FIGO 2018 stage was IB2 in 48 patients (40%). Median follow-up time was 70.2 months and recurrence rate was 24.79%. 39.7% of patients received adjuvant RT due to the presence of unfavourable pathological findings. In multivariate analysis, RT was not found to be a statistically significant prognostic factor for OS (p = 0.584) or DFS (p = 0.559). When comparing patients who met one or two Sedlis criteria, there were no statistically significant differences in OS between RT and no adjuvant treatment in either group.

Conclusion In this retrospective study, no benefits in terms of survival were found in patients who met two Sedlis criteria after radical surgery who received adjuvant RT.

Disclosures The authors declare no conflict of interest.